Comparing Valion Bio, Inc. Common Stock (NASDAQ:VBIO) and Predictive Oncology (NASDAQ:POAI)

Valion Bio, Inc. Common Stock (NASDAQ:VBIO) and Predictive Oncology (NASDAQ:POAI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, risk, valuation and institutional ownership.

Earnings & Valuation

This table compares Valion Bio, Inc. Common Stock and Predictive Oncology”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valion Bio, Inc. Common Stock	$780,000.00	2.65	-$8.88 million	($6.68)	-0.10
Predictive Oncology	$1.66 million	17.86	-$12.66 million	($13.50)	-0.65

Valion Bio, Inc. Common Stock has higher earnings, but lower revenue than Predictive Oncology. Predictive Oncology is trading at a lower price-to-earnings ratio than Valion Bio, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Valion Bio, Inc. Common Stock has a beta of 1.79, indicating that its share price is 79% more volatile than the S&P 500. Comparatively, Predictive Oncology has a beta of 1.35, indicating that its share price is 35% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations for Valion Bio, Inc. Common Stock and Predictive Oncology, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valion Bio, Inc. Common Stock	1	0	0	0	1.00
Predictive Oncology	1	0	0	0	1.00

Profitability

This table compares Valion Bio, Inc. Common Stock and Predictive Oncology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Valion Bio, Inc. Common Stock	N/A	-138.10%	-63.67%
Predictive Oncology	-5,065.23%	-732.73%	-235.55%

Insider and Institutional Ownership

4.3% of Valion Bio, Inc. Common Stock shares are held by institutional investors. Comparatively, 9.0% of Predictive Oncology shares are held by institutional investors. 14.5% of Valion Bio, Inc. Common Stock shares are held by insiders. Comparatively, 1.2% of Predictive Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Valion Bio, Inc. Common Stock beats Predictive Oncology on 8 of the 11 factors compared between the two stocks.

About Valion Bio, Inc. Common Stock

Tivic Health Systems Inc. operates as a health tech company, focuses on developing and commercializing bioelectronic medicine. Its primary product is ClearUP, a bioelectronic medicine for the treatment of sinus and nasal inflammation. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S. online retailers, such as BestBuy and FSAStore and through distributors. Tivic Health Systems, Inc. was incorporated in 2016 and is headquartered in Hayward, California.

About Predictive Oncology

Predictive Oncology Inc. operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples. It operates through four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment provides services that include the application of AI, collaboration projects, and clinical testing. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using a self-contained automated system that conducts self-interaction chromatography screens using additives and excipients included in protein formulations resulting in soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is headquartered in Eagan, Minnesota.